Riskpilot← Back to searchSign inGet full accessBioLean ApS
APSActiveCVR 41078219Algade 2DComputer programming activities · NACE 6210Est. 20203 employeeswww.biolean.dk
Revenue 2024
DKK 1,3M
-51% vs 2023
EBITDA margin
0.6%
-95% vs 2023
Equity ratio
40.0%
Financial strength
Net profit 2024
DKK 7K
-95% vs 2023
| Revenue | DKK 1,3M | -51% |
| EBITDA | DKK 7K | -95% |
| Net profit | DKK 7K | -95% |
| Total assets | DKK 916K | -38% |
| Equity | DKK 366K | +2% |
| Employees | 3 | — |
Legal name
BioLean ApS
CVR number
41078219
Legal form
Anpartsselskab
NACE code
6210 · Computer programming activities
Founded
1. januar 2020
Share capital
DKK 200.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen eller af den administrerende direktør alene.
Company purpose
Selskabets formål er drive virksomhed ved udvikling og implementering af produktionsforbedringsværktøjer samt anden hermed forbunden virksomhed
Address
Algade 2D
Website
www.biolean.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 629 | 1.783 | 1.617 | 2.617 | 1.287 |
| Staff expenses | -401 | -1.986 | -1.543 | -2.480 | -1.280 |
| EBITDA | 228 | -202 | 74 | 137 | 7 |
| Depreciation & amort. | -5 | -8 | -8 | -3 | -0 |
| EBIT | 223 | -210 | 66 | 134 | 7 |
| Net financials | -0 | -2 | -2 | -2 | -1 |
| Profit before tax | 223 | -212 | 64 | 132 | 7 |
| Tax | 47 | -0 | -0 | -0 | -0 |
| Net profit | 176 | -212 | 64 | 132 | 7 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 494 | 577 | 1.156 | 1.472 | 916 |
| Equity | 276 | 64 | 127 | 359 | 366 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 218 | 514 | 1.029 | 1.113 | 550 |
| Total debt | 218 | 514 | 1.029 | 1.113 | 550 |
EBITDA margin
0.6%
This company
15.8%
Market median
-96% vs market
20202024
Equity ratio
40.0%
This company
38.2%
Market median
+5% vs market
20202024
Return on equity
1.9%
This company
18.4%
Market median
-90% vs market
20202024
Net profit margin
0.5%
This company
8.1%
Market median
-94% vs market
20202024
Asset turnover
1.40×
This company
1.12×
Market median
+25% vs market
20202024
Debt / equity
1.50×
This company
0.62×
Market median
-142% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Founder | 2020 | — | — | |
JB Management | Management | 2020 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
FASTFLOW SYSTEMS ApS | Company | 33.3% | 33.3% | 2023 |
| Individual | 33.3% | 33.3% | 2023 | |
| Individual | 15.0% | 15.0% | 2022 | |
| Individual | 5.0% | 5.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FASTFLOW SYSTEMS ApS
BioLean ApS Board members of BioLean ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Isuru Sampath Bandara Abeykoon Udugama | Founder | 0 companies |
| Jesper Bryde-Jacobsen | Management | 0 companies |